Capricor Therapeutics (NASDAQ:CAPR) Shares Up 0.8% – Time to Buy?

Capricor Therapeutics Inc (NASDAQ:CAPR) shares were up 0.8% during mid-day trading on Tuesday . The stock traded as high as $20.50 and last traded at $19.74. Approximately 558,870 shares traded hands during trading, a decline of 48% from the average daily volume of 1,084,159 shares. The stock had previously closed at $19.58.

Wall Street Analyst Weigh In

A number of brokerages recently commented on CAPR. Oppenheimer restated an “outperform” rating and issued a $15.00 price target on shares of Capricor Therapeutics in a research report on Monday, September 23rd. HC Wainwright restated a “buy” rating and issued a $40.00 target price on shares of Capricor Therapeutics in a research report on Wednesday, October 9th. Maxim Group upped their price target on shares of Capricor Therapeutics from $12.00 to $25.00 and gave the stock a “buy” rating in a report on Wednesday, September 25th. Finally, Cantor Fitzgerald reissued an “overweight” rating and issued a $8.00 price objective on shares of Capricor Therapeutics in a research note on Friday, September 20th. One equities research analyst has rated the stock with a sell rating and five have given a buy rating to the company’s stock. According to MarketBeat.com, Capricor Therapeutics currently has an average rating of “Moderate Buy” and an average target price of $22.60.

Capricor Therapeutics Price Performance

The company has a market capitalization of $690.43 million, a price-to-earnings ratio of -24.26 and a beta of 4.01. The firm’s fifty day moving average price is $7.76 and its 200-day moving average price is $6.16.

Capricor Therapeutics (NASDAQ:CAPR) last posted its earnings results on Wednesday, August 7th. The biotechnology company reported ($0.35) EPS for the quarter, missing the consensus estimate of ($0.32) by ($0.03). Capricor Therapeutics had a negative net margin of 102.93% and a negative return on equity of 220.27%. The firm had revenue of $3.97 million during the quarter, compared to the consensus estimate of $4.51 million. On average, research analysts predict that Capricor Therapeutics Inc will post -1.13 earnings per share for the current year.

Insider Activity at Capricor Therapeutics

In other Capricor Therapeutics news, major shareholder Shinyaku Co Ltd Nippon bought 2,798,507 shares of Capricor Therapeutics stock in a transaction on Friday, September 20th. The shares were purchased at an average cost of $5.36 per share, with a total value of $14,999,997.52. Following the acquisition, the insider now directly owns 7,090,351 shares of the company’s stock, valued at $38,004,281.36. The trade was a 0.00 % increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 12.00% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. BNP Paribas Financial Markets acquired a new position in shares of Capricor Therapeutics in the first quarter worth approximately $40,000. Main Street Financial Solutions LLC lifted its position in shares of Capricor Therapeutics by 37.5% in the 2nd quarter. Main Street Financial Solutions LLC now owns 27,500 shares of the biotechnology company’s stock worth $131,000 after purchasing an additional 7,500 shares during the period. SG Americas Securities LLC bought a new stake in shares of Capricor Therapeutics in the 3rd quarter valued at $133,000. Rhumbline Advisers bought a new stake in shares of Capricor Therapeutics in the 2nd quarter valued at $147,000. Finally, Bank of New York Mellon Corp raised its stake in Capricor Therapeutics by 12.8% during the second quarter. Bank of New York Mellon Corp now owns 79,782 shares of the biotechnology company’s stock worth $381,000 after buying an additional 9,040 shares during the last quarter. 21.68% of the stock is owned by institutional investors and hedge funds.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.